



Allena Pharmaceuticals To Present Data on Lead Program ALLN-177 at ASN Kidney Week 2014

November 10, 2014

NEWTON, Mass. – Nov. 10, 2014 – Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on developing and commercializing innovative non- systemic oral protein therapeutics to treat metabolic and orphan diseases, today announced that the company will present Phase 1 data on ALLN-177, its lead product for the treatment of hyperoxaluria, at the American Society of Nephrology (ASN) Kidney Week 2014, being held November 11-16, 2014 at the Pennsylvania Convention Center in Philadelphia.

The schedule for Allena's oral presentation is as follows:

Title: An Oral Enzyme (ALLN-177) Reduces Dietary Hyperoxaluria (#2056)

Date and Time: Saturday, November 15, 2014, 4:30-6:30 p.m.

Session Title: Stones and Bones: Pathogenesis and Treatment

Presenter: Craig Langman, M.D., The Isaac A Abt MD Professor of Kidney Diseases, Feinberg School of Medicine, Northwestern University, Head, Kidney Diseases, Lurie Children's Hospital of Chicago

Location: Room 204-A

Abstract Program: SA-OR085

About Hyperoxaluria

Hyperoxaluria is a serious metabolic disorder and is one of the major risk factors for nephrolithiasis, nephrocalcinosis, and oxalate nephropathy that leads to chronic kidney disease. Hyperoxaluria is a direct result of either hyper-absorption of oxalate from the diet (secondary hyperoxaluria) or from overproduction of oxalate due to a hereditary enzyme deficiency in the liver (primary hyperoxaluria). No effective pharmacologic treatment exists for hyperoxaluria.

About ALLN-177

Allena's lead product, ALLN-177 is an orally administered highly active recombinant oxalate degrading enzyme for the chronic management of hyperoxaluria and kidney stones. ALLN-177 has the potential to degrade both dietary and endogenously produced oxalate in the GI tract and decrease its absorption. This degradation of oxalate may reduce or prevent oxalate deposition as calcium oxalate crystals or stones in the kidneys and urinary tract, as well as other related complications. ALLN-177 is in an ongoing Phase 2 clinical trial in patients with secondary hyperoxaluria.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases. The company's proven approach enables the design and development of oral protein therapies that remain in the gastrointestinal (GI) tract, where the protein exerts its therapeutic effect by

reducing toxic metabolites without being absorbed into the bloodstream. Led by a proven management team with deep expertise in protein therapeutic design and development, Allena is committed to bringing breakthrough new treatments to patients with unmet medical needs. For more information, please visit www.allenapharma.com.

Company Contact: Robert Gallotto
Chief Operating Officer (617) 467-4577

Media Contact:
Katie Engleman
Pure Communications (910) 509-3977